Abstract
Traditionally, methicillin-resistant Staphylococcus aureus (MRSA) has been seen as an infection control problem in healthcare communities. It is now clear that antibiotic use is also an important factor in the control of MRSA, both in the treatment of infection and also, paradoxically perhaps, as a cause of the MRSA problem, in the same way that antibiotic use causes Clostridium difficile disease. At both levels, major improvements in the quality of our antibiotic use are required, particularly antibiotic stewardship to reduce the selection, maintenance and transmission of MRSA strains. In addition, new agents are required to reduce our reliance on glycopeptides for the treatment of serious MRSA infections. Daptomycin has great promise in this regard as its rapid bactericidal activity makes it particularly suitable for the treatment of bacteraemia and endocarditis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
